CAI
Clinical Asset Index
by VOS Supply Group
Drugs · acquisition-cost intelligence

Fluticasone Propionate and Salmeterol HFA

fluticasone propionate and salmeterol xinafoate· ingredient salmeterolAdrenergics in combination with corticosteroids or other drugs, excl. anticholinergics· FLUTICASONE PROPIONATE 115 ug/1; SALMETEROL XINAFOATE 21 ug/1; FLUTICASONE PROPIONATE 230 ug/1; SALMETEROL XINAFOATE 21 ug/1; FLUTICASONE PROPIONATE 45 ug/1; SALMETEROL XINAFOATE 21 ug/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per GM
$20.32
NADAC — pharmacy acquisition cost, not a retail/cash price

Acquisition-cost history

Weekly NADAC per GM — the trend nobody else shows. 6 weeks.

2025-12-172026-05-20

Same-ingredient options by acquisition cost

Other salmeterol products, cheapest acquisition cost first. Per GM — confirm strength/form equivalence before switching.

ProductNADAC / GMvs this
ADVAIR DISKUS$1.33−$19.00
ADVAIR DISKUS$3.12−$17.20
SEREVENT DISKUS$6.74−$13.58
ADVAIR HFA$22.72+$2.40
AirDuo RespiClick$110.30+$89.97

Medicare Part D coverage · CY2026

On 30 plan formularies · typical tier 1
Prior auth 0% · Step therapy 0% · Quantity limit 70% of formularies

Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.